This financing allows Oncodesign to have a current cash position of €31.2 million and to continue its growth strategy without any slowdown

Regulatory News:

ONCODESIGN (Paris:ALONC) (ALONC – FR0011766229), a biopharmaceutical group specialized in precision medicine, has received the agreement in principal of its banking partners to obtain a State-Guaranteed Loan of €15.9 million.

This loan, 90% guaranteed by the French State within the framework of the State-Guaranteed Loan (decrees of March 23 and April 17, 2020 enabling credit establishments and finance companies to benefit from a State guarantee, amending the Finance Act n° 2020-289 of March 23, 2020), will have a 1-year maturity that may be extended for up to a further 5 years (September 2026) at the Company’s discretion.

This new funding, requested within the framework of the measures adopted by the French government to support French companies in the face of the ongoing public health crisis, allows the Company to benefit from the support of Bpifrance, Crédit Agricole Champagne-Bourgogne, Caisse d’Epargne Bourgogne Franche Comté, CIC Lyonnaise de Banque and Société Générale.

Philippe GENNE, Chairman and Chief Executive Officer of Oncodesign, says: “We would like to thank our banking partners and the French State for their support and their renewed trust in our company. This support will enable us to be better equipped to face the uncertainty generated by the public health situation, which looks as if it may persist through to the end of the year, and to thus calmly pursue our activity with a significantly-strengthened cash position”.


Founded 25 years ago by Dr. Philippe Genne, the Company’s CEO and Chairman, Oncodesign is a biopharmaceutical company dedicated to precision medicine. With its unique experience acquired by working with more than 800 clients, including the world’s largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis, medical imaging and Artificial Intelligence, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over $65 billion by 2027 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Servier. Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 233 employees and subsidiaries in Canada and the USA.


This press release contains certain forward - looking statements and estimates concerning the Company’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the Company’s control. Consequently, the actual results, financial condition, performances and/or achievements of the Company or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and the Company undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.

Oncodesign Philippe Genne Chairman and CEO Tel. : +33 (0)3 80 78 82 60

NewCap Investor Relations Mathilde Bohin / Louis-Victor Delouvrier Tel. : +33 (0)1 44 71 94 95

NewCap Media Relations Arthur Rouillé Tel. : +33 (0)1 44 71 00 15

Grafico Azioni Oncodesign (EU:ALONC)
Da Ott 2020 a Nov 2020 Clicca qui per i Grafici di Oncodesign
Grafico Azioni Oncodesign (EU:ALONC)
Da Nov 2019 a Nov 2020 Clicca qui per i Grafici di Oncodesign